Emma Hathorn1, Catherine Opie, Penny Goold. 1. Department of Genitourinary Medicine, Whittall Street Clinic, Whittall Street, Birmingham, B4 6DH, UK. emma.hathorn@nhs.net
Abstract
BACKGROUND: There is no UK guidance specifically for the management of rectal Chlamydia trachomatis yet there is documented treatment failure with single-dose azithromycin suggesting that test of cure (TOC) and alternative treatment may be needed. OBJECTIVES: To evaluate the efficacy of single-dose azithromycin compared with 1 week of doxycycline in the treatment of rectal C trachomatis. METHODS: Data were collected prospectively on all patients diagnosed with rectal C trachomatis who received azithromycin 1 g stat between 1 January and 30 June 2010 and between 1 October 2010 and 31 March 2011 following a local change in treatment protocol to 1 week of doxycycline 100 mg twice a day. Information was collected on gender, concurrent sexually transmitted infections, treatment received, re-infection risk, re-treatment and TOC at 6 weeks. RESULTS: 11 patients (26.2%) had a positive TOC following treatment with stat azithromycin. The risk of re-infection was excluded in two, identifying nine of the 11 (81.8%) as treatment failures. Two patients had a positive TOC following treatment with 1 week of doxycycline, both were found to have a risk of re-infection. There was a significantly higher treatment failure rate in patients receiving azithromycin (p=0.0025). CONCLUSIONS: A higher treatment failure rate was found following azithromycin for rectal C trachomatis than previously published. If azithromycin is used for treatment of rectal C trachomatis, TOC may be required or alternative treatment with doxycycline may be preferable, but further data are required.
BACKGROUND: There is no UK guidance specifically for the management of rectal Chlamydia trachomatis yet there is documented treatment failure with single-dose azithromycin suggesting that test of cure (TOC) and alternative treatment may be needed. OBJECTIVES: To evaluate the efficacy of single-dose azithromycin compared with 1 week of doxycycline in the treatment of rectal C trachomatis. METHODS: Data were collected prospectively on all patients diagnosed with rectal C trachomatis who received azithromycin 1 g stat between 1 January and 30 June 2010 and between 1 October 2010 and 31 March 2011 following a local change in treatment protocol to 1 week of doxycycline 100 mg twice a day. Information was collected on gender, concurrent sexually transmitted infections, treatment received, re-infection risk, re-treatment and TOC at 6 weeks. RESULTS: 11 patients (26.2%) had a positive TOC following treatment with stat azithromycin. The risk of re-infection was excluded in two, identifying nine of the 11 (81.8%) as treatment failures. Two patients had a positive TOC following treatment with 1 week of doxycycline, both were found to have a risk of re-infection. There was a significantly higher treatment failure rate in patients receiving azithromycin (p=0.0025). CONCLUSIONS: A higher treatment failure rate was found following azithromycin for rectal C trachomatis than previously published. If azithromycin is used for treatment of rectal C trachomatis, TOC may be required or alternative treatment with doxycycline may be preferable, but further data are required.
Authors: Nicole H T M Dukers-Muijrers; Genevieve A F S van Liere; Petra F G Wolffs; Casper Den Heijer; Marita I L S Werner; Christian J P A Hoebe Journal: Antimicrob Agents Chemother Date: 2014-10-13 Impact factor: 5.191
Authors: Christine M Khosropour; Julia C Dombrowski; Lindley A Barbee; Lisa E Manhart; Matthew R Golden Journal: Sex Transm Dis Date: 2014-02 Impact factor: 2.830
Authors: Christine M Khosropour; Olusegun O Soge; Robert Suchland; Gina Leipertz; Anna Unutzer; Rushlenne Pascual; Kevin Hybiske; Lindley A Barbee; Lisa E Manhart; Julia C Dombrowski; Matthew R Golden Journal: J Infect Dis Date: 2019-07-02 Impact factor: 5.226
Authors: Mohamed A Seleem; Nicholas A Wood; Amanda J Brinkworth; Srikanth Manam; Rey A Carabeo; Ashlesh K Murthy; Scot P Ouellette; Martin Conda-Sheridan Journal: ACS Infect Dis Date: 2021-12-22 Impact factor: 5.578